Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20534535
Mund T, Pelham HR (2010) Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2. Proc Natl Acad Sci U S A 107, 11429-34 20534535
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF augment treatment-induced increase
EGF NDFIP1 (human) increase Ndfip1 siRNA inhibits
EGF NDFIP2 (human) no effect upon treatment-induced increase NDFIP2 siRNA -no effect on increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
EGF NDFIP1 (human) no effect upon treatment-induced increase Ndfip1 siRNA- no effect
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
EGF NDFIP1 (human) no effect upon treatment-induced increase Ndfip1 siRNA- no effect
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
EGF NDFIP1 (human) no effect upon treatment-induced increase Ndfip1 siRNA- no effect
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
U0126 EGF inhibit treatment-induced increase
EGF NDFIP1 (human) no effect upon treatment-induced increase Ndfip1 siRNA- no effect
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase later increase (12-18 min)
EGF NDFIP1 (human) inhibit treatment-induced increase Ndffip1 siRNA augments
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase later increase (12-18 min)
EGF NDFIP1 (human) inhibit treatment-induced increase Ndffip1 siRNA augments
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase later increase (12-18 min)
EGF NDFIP1 (human) inhibit treatment-induced increase Ndffip1 siRNA augments
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase later increase (12-18 min)
EGF NDFIP1 (human) inhibit treatment-induced increase Ndffip1 siRNA augments
EGF NDFIP2 (human) inhibit treatment-induced increase NDFIP2 siRNA augments increase

Y151-p - NDFIP2 (human)
Modsite: TDSSPPPySSITVEV SwissProt Entrez-Gene
Orthologous residues
NDFIP2 (human): Y151‑p, NDFIP2 (mouse): Y126‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

Y167-p - NDFIP2 (human)
Modsite: TTSDTEVyGEFyPVP SwissProt Entrez-Gene
Orthologous residues
NDFIP2 (human): Y167‑p, NDFIP2 (mouse): Y142‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)

Y171-p - NDFIP2 (human)
Modsite: TEVyGEFyPVPPPyS SwissProt Entrez-Gene
Orthologous residues
NDFIP2 (human): Y171‑p, NDFIP2 (mouse): Y146‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) transfection of wild-type enzyme, co-immunoprecipitation, mutation in upstream enzyme recognition motif Y171 phosphorylation is required for Src phosphorylation of Ndfip1.
Downstream Regulation
Effect of modification (function):  molecular association, regulation, phosphorylation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
LYN (human) SH2, SH3 Induces activity, induced co-immunoprecipitation
Comments:  Y167, Y177 and Y186 phosphorylation are dependent on Y171 phosphorylation

Y177-p - NDFIP2 (human)
Modsite: FyPVPPPySVATSLP SwissProt Entrez-Gene
Orthologous residues
NDFIP2 (human): Y177‑p, NDFIP2 (mouse): Y152‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human

Y186-p - NDFIP2 (human)
Modsite: VATSLPTyDEAEkAk SwissProt Entrez-Gene
Orthologous residues
NDFIP2 (human): Y186‑p, NDFIP2 (mouse): Y161‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human